SOPHiA GENETICS (NASDAQ:SOPH) CEO Jurgi Camblong Sells 2,600 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Jurgi Camblong sold 2,600 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $4.85, for a total value of $12,610.00. Following the completion of the transaction, the chief executive officer directly owned 3,731,450 shares of the company’s stock, valued at approximately $18,097,532.50. This trade represents a 0.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total value of $12,150.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total value of $21,398.22.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH opened at $4.86 on Thursday. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The business has a 50-day simple moving average of $4.77 and a two-hundred day simple moving average of $4.68. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. The firm has a market cap of $332.86 million, a price-to-earnings ratio of -9.53 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.71 million during the quarter, compared to analysts’ expectations of $21.20 million. On average, analysts expect that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Wall Street Analyst Weigh In

SOPH has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim boosted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, BTIG Research restated a “buy” rating and set a $7.00 price target on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Large investors have recently made changes to their positions in the company. Alta Wealth Advisors LLC bought a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at about $6,708,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at about $54,000. Polen Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at about $102,000. 1492 Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at about $973,000. Finally, Royce & Associates LP bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at about $2,009,000. 31.59% of the stock is currently owned by institutional investors.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: CEO Jurgi Camblong executed two Rule 10b5‑1 sales (2,600 and 2,500 shares at ~$4.85–4.86). CEO still holds ~3.7M shares. SEC filing
• Neutral Sentiment: CFO George Cardoza reported multiple small sales (~2,520; 2,413 shares) under a 10b5‑1 plan to cover taxes; remaining holdings stay large (~292–295k shares). SEC filing
• Neutral Sentiment: CTO Abhimanyu Verma sold several tranches (2,519; 1,030 shares) under a 10b5‑1 plan; still owns ~204–205k shares. SEC filing
• Neutral Sentiment: President Ross Muken and other senior managers (Philippe Menu, Zhenyu Xu, Manuela Valente, Well Daan Van, Kevin Puylaert) reported multiple planned sales of ~600–2,700 shares each to cover tax obligations; each filing cites Rule 10b5‑1 plans. Representative filings: Menu, Xu, Valente. Menu SEC filing
• Neutral Sentiment: Collectively the insider sales are modest relative to total insider holdings and were executed under pre‑arranged plans (tax withholding stated as purpose), which reduces negative informational signal but can still create short-term selling pressure.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.